November 18th, 2022. Today, Applied Cells Inc. and GenScript USA Incorporated announced their strategic collaboration to deliver combined cell isolation solutions for cell therapy drug development worldwide. Under this collaboration, GenScript will develop and supply its proprietary research and cGMP grade CytoSinct™ reagents for use in developing CAR-T and other Cell Therapy products on the Applied Cells MARS® Platform.
/PRNewswire/ Today, Applied Cells Inc. and GenScript USA Incorporated announced their strategic collaboration to deliver combined cell isolation solutions.
/PRNewswire/ Applied Cells Inc. and STEMCELL Technologies Canada Inc. have announced their collaboration to deliver a new high-performance cell separation.
/PRNewswire/ Applied Cells, Inc., announced today that the company will unveil its MARS® Bar GMP-Ready System at the SLAS Conference in Boston on February 7..